Precision Targeting, Bone Renewal: Qilu Pharma Satellite Symposium at COA 2023 Highlights LUKEXIN (Denosumab Injection)
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Reproduction of this article is prohibited without authorization.
Opening Ceremony Venue
Satellite Venue
Satellite Meeting byProfessor Jiang Qing from the Affiliated Drum Tower Hospital of Nanjing University Medical School,Prof. Lianxin Li from the Provincial Hospital Affiliated to Shandong First Medical University and Prof. Kun Zhang from Honghui Hospital Affiliated to Xi'an Jiaotong University School of Medicine presided over the event.
Professor Longpo Zheng from the Tenth People's Hospital of Shanghai
"New Advances in the Treatment of Fragility Fractures"
Professor Zheng Longpo first introduced the clinical status of osteoporotic fractures and the advances in diagnosis and treatment of osteoporotic fractures.The situation of osteoporotic fractures in people over 50 years old is severe both in China and abroad, with a heavy disease burden. Osteoporotic fractures have a significant impact on patients, reducing their quality of life and harming their healthy lifespan.
Professor Longpo Zheng's Lecture
Professor Zheng showcased significant advancements in the field of osteoporotic fractures, with research indicating:
Various factors, including age, BMI, education level, medical history (hypertension, diabetes, autoimmune hepatitis), age at menarche, age at menopause, exercise, etc., are associated with osteoporotic fractures.
QCT Has Stronger Discriminatory Power in Differentiating Osteoporotic Vertebral Fracture Risk
Conservative treatment for vertebral compression fractures is an important factor leading to overall sagittal imbalance in patients.
Compared with conservative treatment, vertebroplasty within 3 weeks of fracture is more beneficial.
For the treatment of vertebral compression fractures, percutaneous vertebroplasty is more time-saving and economical compared to balloon kyphoplasty, but kyphoplasty has advantages in reducing cement leakage and increasing postoperative vertebral height.
Denosumab is superior to various drugs, including bisphosphonates, in preventing the risk of vertebral fractures.
Efficacy of Sequential Treatment Significantly Superior to Bisphosphonate Monotherapy in High-Risk Patients with Osteoporotic Fractures
Treatment with bisphosphonates for 3 years or longer increases the risk of atypical femoral fractures (AFFs) and osteonecrosis of the jaw (ONJ).。
Professor Zheng Longpo said that the approval and market launch of Qilu Pharmaceutical's Lukexin marks a further improvement in China's independent research and development capabilities, providing a new option for Chinese patients with fragility fractures.
Professor Shan Lequn from the Honghui Hospital Affiliated to the Medical College of Xi'an Jiaotong University
New Treatment Options for Fragility Fractures
Subsequently, Professor Shan Lequn shared a new treatment plan for fragility fractures:
Fragility fractures are a serious health issue, associated with high rates of disability and mortality, significantly reducing patients' quality of life and life expectancy.Fragility fractures are common in postmenopausal women, often occurring in the vertebrae, hip, wrist, and other areas, with incidence increasing with age. The causes of fragility fractures include low bone mass and non-skeletal factors (such as a tendency to fall). Therefore, one of the basic principles of treating fragility fractures is anti-osteoporosis treatment.
Professor Dan Lequn's Lecture
Numerous study results indicate that denosumab can significantly increase BMD and reduce the risk of fractures and re-fractures. In terms of reducing the incidence of hip fractures in elderly frail patients, denosumab is more effective than teriparatide and zoledronic acid; during denosumab treatment, patients experience significant improvement in back pain-related activity limitations and HRQOL; the risk of re-fracture after fragility fractures is high, making standardized postoperative anti-osteoporosis treatment crucial. China’s guidelines for standardized anti-osteoporosis treatment after fragility fractures recommend that all patients who have undergone surgery for fragility fractures should receive standardized anti-osteoporosis drug therapy.
China-produced denosumab Rukexin, after 11 years of development, was approved in September 2023. In the context of centralized procurement, Qilu Pharmaceutical's substantial investment in research from the early stages through to its final approval is something they are willing to share with everyone. It is also hoped that Qilu Pharmaceutical will continue on its path of innovation, providing better and newer osteoporosis treatments for patients in China.
Professor Shan Lequn explained the risks and treatment of fragility fractures, with a particular focus on comparing the efficacy of denosumab with other drugs. This will undoubtedly be beneficial for clinical practice.
Professor Xiaotao Wu from Zhongda Hospital, Southeast University
New Prospects for the Application of RANKL Inhibitors in Orthopedics
Professor Xiaotao Wu from Zhongda Hospital Affiliated to Southeast University shared new prospects for the application of RANKL inhibitors in orthopedics. He mentioned that there are many complications after joint replacement surgery, among which aseptic loosening of the prosthesis and periprosthetic fractures are closely related to bone loss around the prosthesis. As an anti-bone resorption drug, denosumab has the effect of reducing bone resorption and increasing bone mass.
Professor Xiaotao Wu's Lecture
Numerous studies have shown that denosumab can effectively reduce osteolysis after total hip arthroplasty and prevent early periprosthetic bone loss in non-cemented total hip arthroplasty. Similarly, denosumab can also reduce periprosthetic bone loss at the tibial end after total knee arthroplasty.
Finally, Zhang Kun, Dean of the Honghui Hospital Affiliated to the Medical College of Xi'an Jiaotong University, presided over the discussion session:
The Wonderful Discussion Scene by the Professors
Professor Zhang Kun first asked the experts present: "Do you routinely treat osteoporosis after fracture treatment?"
Director Wu Xiaotao said that they would carry out routine osteoporosis treatment, and assess the bone condition before surgery, measuring bone density. Special measures would be taken for patients with bone density below -3.0;
Professor Jiang Qing said that they not only treat osteoporosis routinely after surgery, but if severe osteoporosis is found before the operation, treatment should be started preoperatively.
Professor Li Lianxin said that they would add anti-osteoporosis drugs after treating elderly fractures.
At the end of the conference, Professor Zhang Kun made a summary, stating that this was a very good satellite meeting and he had learned a lot. We have now entered an aging society, and osteoporosis should not be underestimated. He also expressed hope that good drugs will be used at the best time and in the optimal place.Technological Innovation Enhances Health and Well-beingInThisAt the upcoming COA conference, this satellite meetingSuccessfully completed, hoping that Qilu Pharmaceutical will develop more effective drugs in the future to jointly contribute to patients' recovery with better products.
Qilu Pharmaceutical is a large comprehensive modern pharmaceutical enterprise in China, mainly engaged in the research, production, and sales of anti-tumor drugs, cardiovascular and cerebrovascular drugs, anti-infective drugs, respiratory system drugs, and drugs for the nervous system. Qilu Pharmaceutical always adheres to the core corporate values of "Great Medicine with Utmost Sincerity, Family and Country under Heaven," focusing on patients and ensuring drug quality throughout all processes. With the launch of Lucosin®, Qilu Pharmaceutical will continue to promote more high-quality, affordable domestically produced medicines in the fields of orthopedics and osteoporosis.
This articleThis article only represents the author's personal views, not the official position of Gujin Zhongwai. It is hoped that everyone will make rational judgments and apply them in a targeted manner.
SubmissionEmail: gujinzw@163.com
